1. Medtech Insight

Minute Insight: Insulet Launches Omnipod 5 US-Wide Following Trial Period

 
• By Barnaby Pickering

After six months, the Omnipod 5 has seen its limited market launch expanded to cover the entirety of the US market.

Minute Insight
• Source: Informa/Alamy

Insulet has announced the full US market launch of its Omnipod 5 Automated Insulin Delivery System, which will now be available in retail pharmacies and through mail order for type I diabetes patients aged six years and older on a “pay-as-you-go" basis.

The Omnipod 5 is a tubeless insulin pump system that can integrate with Dexcom’s G6 continuous glucose monitor. It can also be controlled through a smartphone, though currently only some Android devices are compatible. Every five minutes, the system adjusts insulin delivery depending on glucose readings

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

More from Device Area

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

 
• By Shubham Singh

In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By Elizabeth Orr

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.